Published in Proc Natl Acad Sci U S A on December 22, 2014
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study (APPRoAcH-p) | NCT03655704
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol (2015) 1.46
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep (2016) 1.46
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. ACS Chem Biol (2015) 1.33
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep (2015) 0.97
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther (2016) 0.91
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Theranostics (2016) 0.89
The kinome 'at large' in cancer. Nat Rev Cancer (2016) 0.88
BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. EBioMedicine (2015) 0.88
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. Elife (2015) 0.84
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep (2016) 0.80
Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma. Oncol Lett (2016) 0.80
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res (2016) 0.79
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget (2016) 0.78
Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms. Proc Natl Acad Sci U S A (2016) 0.78
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. Oncogenesis (2017) 0.78
Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations. Mol Cell (2016) 0.77
Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. J Am Soc Nephrol (2016) 0.77
Concomitant BET and MAPK blockade for effective treatment of ovarian cancer. Oncotarget (2016) 0.76
BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Oncotarget (2016) 0.76
The Quest for Targets Executing MYC-Dependent Cell Transformation. Front Oncol (2016) 0.76
Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. BMC Cancer (2016) 0.75
The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer. Clin Cancer Res (2016) 0.75
Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival. Mol Clin Oncol (2015) 0.75
RNAi screens identify CHD4 as an essential gene in breast cancer growth. Oncotarget (2016) 0.75
BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). Oncotarget (2017) 0.75
Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin. Mol Clin Oncol (2017) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Selective inhibition of BET bromodomains. Nature (2010) 18.79
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Towards a knowledge-based Human Protein Atlas. Nat Biotechnol (2010) 11.05
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature (2014) 5.45
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer (2010) 4.06
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell (2013) 2.83
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A (2012) 2.52
Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell (2014) 1.89
Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther (2010) 1.85
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res (2002) 1.84
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology (2012) 1.71
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res (2013) 1.64
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer (2004) 1.39
Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett (2013) 1.26
Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS One (2011) 1.25
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One (2013) 1.19
mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol (2014) 1.13
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin Cancer Res (2013) 1.10
Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. BMC Cancer (2012) 0.99
Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol (2005) 0.93
p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors. Oncogene (2011) 0.91
Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors. Biomed Rep (2013) 0.90
Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. Int J Biochem Cell Biol (2013) 0.85
NM23 as a prognostic biomarker in ovarian serous carcinoma. Mod Pathol (2008) 0.84
Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathol Oncol Res (2014) 0.81